Home » Stocks » LJPC

La Jolla Pharmaceutical Company (LJPC)

Stock Price: $5.40 USD 0.05 (0.93%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $5.45 +0.05 (0.93%) Jan 19, 7:24 PM
Market Cap 147.86M
Revenue (ttm) 29.72M
Net Income (ttm) -61.18M
Shares Out 27.37M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $5.40
Previous Close $5.35
Change ($) 0.05
Change (%) 0.93%
Day's Open 5.38
Day's Range 5.20 - 5.84
Day's Volume 650,455
52-Week Range 3.40 - 8.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patient...

Zacks Investment Research - 3 weeks ago

La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patient...

GlobeNewsWire - 5 months ago

SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies...

GlobeNewsWire - 5 months ago

SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Exe...

GlobeNewsWire - 5 months ago

-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from...

GlobeNewsWire - 6 months ago

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights

Zacks Investment Research - 7 months ago

La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...

Zacks Investment Research - 8 months ago

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...

Benzinga - 10 months ago

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, CANF, ENTA, LLY, OPK, RHHBY
GlobeNewsWire - 10 months ago

SAN DIEGO, March 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impro...

Zacks Investment Research - 10 months ago

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 10 months ago

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.

Benzinga - 1 year ago

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.

Other stocks mentioned: APTX, OSMT
GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...

Market Watch - 1 year ago

Shares of La Jolla Pharmaceutical Company fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate it...

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -0.93% and -18.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead ...

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 1 year ago

This year, for the first time in many years, active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

Other stocks mentioned: AXSM, BHC, CHNG, HQY
GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended ...

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CDEV, CISN, NOG, VER
GlobeNewsWire - 1 year ago

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended t...

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...

Zacks Investment Research - 1 year ago

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

Seeking Alpha - 1 year ago

La Jolla Pharmaceutical announced positive results from its phase 2 study using LJPC-401 to treat patients with hereditary hemochromatosis.

Seeking Alpha - 1 year ago

Successful turnaround stories are like Cinderella bioscience stocks. They do not come around often but the profits from a successful turnaround are phenomenal.

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.

The Motley Fool - 1 year ago

A mid-stage clinical trial has investors excited about the biotech's future.

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 1 year ago

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 1 year ago

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

Other stocks mentioned: GLMD, INO, MNKD, VKTX

About LJPC

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 1994
Stock Exchange
NASDAQ
Ticker Symbol
LJPC
Full Company Profile

Financial Performance

In 2019, LJPC's revenue was $23.05 million, an increase of 129.26% compared to the previous year's $10.06 million. Losses were -$116.51 million, -41.59% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for LJPC stock is "Buy." The 12-month stock price forecast is 10.92, which is an increase of 102.22% from the latest price.

Price Target
$10.92
(102.22% upside)
Analyst Consensus: Buy